Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
Eli Lilly has signed a deal worth up to $3.25 billion with China's InnoCare to develop new medicines.
InnoCare Pharma
HKEX: 09969 TBD MCAP
InnoCare is a biologics company covered in the openbionews harvest.
Company Info
Recent News
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test.